Monthly Archives: March 2014

Biothera to Present Phase 2b NSCLC Data at  ESMO 2014 European Lung Cancer Conference

Biothera to Present Phase 2b NSCLC Data at ESMO 2014 European Lung Cancer Conference

EAGAN, MN — March 27, 2014 — Biothera will present data from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology’s 2014 European Lung Cancer Conference on March 28 in Geneva, Switzerland. The company will give a presentation about its randomized trial in patients with previously untreated advanced NSCLC evaluating Biothera’s immunotherapy drug, Imprime PGG®. The...

Read More


Biothera Presents Pharmacokinetic Data for its Cancer Immunotherapy Imprime PGG

ATLANTA — March 21, 2014 —Pharmacokinetic (PK) data supporting the dose and schedule regimens of Biothera’s phase 3 cancer immunotherapy Imprime PGG® are being presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting this week. The results are based on population pharmacokinetic data generated from four clinical trials that included two phase 1 safety studies in healthy volunteers, a phase 1b/2 study...

Read More


Biothera Data Strengthens Imprime PGG Biomarker Correlation

Biothera Data Strengthens Imprime PGG Biomarker Correlation

EAGAN, MN — March 10, 2014 — Biothera will present data today demonstrating a threshold presence of anti-beta glucan antibodies (ABA), IgG and IgM are predictive of binding of the company’s cancer immunotherapy Imprime PGG® to neutrophils and monocytes, which can then recognize and kill cancer cells. The presentation is part of the Keystone Symposia on Inflammation, Infection and Cancer in Whistler, British Columbia, Canada....

Read More


Biothera Invited to Participate in Panel Discussion on Cancer Immunotherapy at BIO Europe

Biothera Invited to Participate in Panel Discussion on Cancer Immunotherapy at BIO Europe

EAGAN, MN — March 10, 2014 — Biothera Chief Scientific Officer Myra Patchen, Ph.D. has been invited to participate in an expert panel discussion on the revolution of cancer immunotherapies today at BIO Europe in Turin, Italy. The session entitled, “From Pariah toDarling: Biopharma Finally Courts Immunotherapies,” will feature global leaders in the development of immunotherapies that utilize the body’s own immune system to fight...

Read More


Dr. Ada Braun Joins Biothera as Chief Medical Officer

EAGAN, MN — March 4, 2014 — Biothera announced today the appointment of Ada H. Braun, M.D., Ph.D. as Chief Medical Officer responsible for the clinical and regulatory development of Imprime PGG®, the company’s Phase 3 cancer immunotherapy drug. Most recently, Dr. Braun was Executive Medical Director, Global Development, Hematology/Oncology at Amgen, Inc. Dr. Braun has extensive experience in the treatment of both liquid and...

Read More